More Information about Clinical Studies evaluating IMM-101
For more information about ongoing studies with IMM-101, please see below:
IMM-101-015, Advanced melanoma (United Kingdom)
LAPC-2, Locally advanced pancreatic cancer (Netherlands)
MEPANC-1, oligo metastatic pancreatic cancer (Netherlands)
CCTG IC.8, COVID-19 and cancer patients (Canada)
We cannot legally provide individual advice concerning the benefits of IMM-101. Your physician/medical team would need to make contact with the relevant trial Principal Investigator whose details, together with other information regarding our clinical trials, can be found on www.clinicaltrials.gov.
IMM-101 is an unlicensed product that is only available for use in appropriately authorised clinical trials.